These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 33033402)

  • 1. CMAP changes upon symptom onset and during treatment in spinal muscular atrophy patients: lessons learned from newborn screening.
    Weng WC; Hsu YK; Chang FM; Lin CY; Hwu WL; Lee WT; Lee NC; Chien YH
    Genet Med; 2021 Feb; 23(2):415-420. PubMed ID: 33033402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlations between clinical motor scores and CMAP in patients with type 2 spinal muscular amyotrophy treated with nusinersen.
    Richard M; Barrois R; Desguerre I; Deladrière E; Leloup-Germa V; Barnerias C; Gitiaux C
    Arch Pediatr; 2024 Jan; 31(1):26-31. PubMed ID: 37989659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One Year of Newborn Screening for SMA - Results of a German Pilot Project.
    Vill K; Kölbel H; Schwartz O; Blaschek A; Olgemöller B; Harms E; Burggraf S; Röschinger W; Durner J; Gläser D; Nennstiel U; Wirth B; Schara U; Jensen B; Becker M; Hohenfellner K; Müller-Felber W
    J Neuromuscul Dis; 2019; 6(4):503-515. PubMed ID: 31594245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years.
    Vill K; Schwartz O; Blaschek A; Gläser D; Nennstiel U; Wirth B; Burggraf S; Röschinger W; Becker M; Czibere L; Durner J; Eggermann K; Olgemöller B; Harms E; Schara U; Kölbel H; Müller-Felber W
    Orphanet J Rare Dis; 2021 Mar; 16(1):153. PubMed ID: 33789695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study.
    Kariyawasam DS; D'Silva AM; Sampaio H; Briggs N; Herbert K; Wiley V; Farrar MA
    Lancet Child Adolesc Health; 2023 Mar; 7(3):159-170. PubMed ID: 36669516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of risdiplam efficacy in 5q spinal muscular atrophy: A systematic comparison of electrophysiologic with clinical outcome measures.
    Kessler T; Sam G; Wick W; Weiler M
    Eur J Neurol; 2024 Jan; 31(1):e16099. PubMed ID: 37823715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Facial nerve vulnerability in spinal muscular atrophy and motor unit number index of the orbicularis oculi muscle.
    Barp A; Carraro E; Salmin F; Lizio A; Cheli M; Sansone V
    Muscle Nerve; 2023 May; 67(5):401-406. PubMed ID: 36861214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in electrophysiological findings of spinal muscular atrophy type I after the administration of nusinersen and onasemnogene abeparvovec: two case reports.
    Mizuno T; Kanouchi T; Tamura Y; Hirata K; Emoto R; Suzuki T; Kashimada K; Morio T
    BMC Neurol; 2023 Oct; 23(1):392. PubMed ID: 37907848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nusinersen induces detectable changes in compound motor action potential response in spinal muscular atrophy type 1 patients with severe impairment of motor function.
    Ueda Y; Egawa K; Kawamura K; Ochi N; Goto T; Kimura S; Narugami M; Nakakubo S; Nakajima M; Manabe A; Shiraishi H
    Brain Dev; 2024 Mar; 46(3):149-153. PubMed ID: 38103972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal Assessment of Timed Function Tests in Ambulatory Individuals with SMA Treated with Nusinersen.
    Krosschell KJ; Brown L; Hoffman K; Zumpf KB; Munson H; Bidwell J; Schulte DP; Schwaede AN; Buehner AN; DiDonato CJ; Kuntz NL; Rao VK
    J Neuromuscul Dis; 2023; 10(3):337-348. PubMed ID: 36872785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy.
    Lee BH; Waldrop MA; Connolly AM; Ciafaloni E
    Muscle Nerve; 2021 Aug; 64(2):153-155. PubMed ID: 33959970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening.
    Glascock J; Sampson J; Haidet-Phillips A; Connolly A; Darras B; Day J; Finkel R; Howell RR; Klinger K; Kuntz N; Prior T; Shieh PB; Crawford TO; Kerr D; Jarecki J
    J Neuromuscul Dis; 2018; 5(2):145-158. PubMed ID: 29614695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy.
    Alves CRR; Zhang R; Johnstone AJ; Garner R; Nwe PH; Siranosian JJ; Swoboda KJ
    Neurology; 2020 Mar; 94(9):e921-e931. PubMed ID: 31882526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newborn Screening for Spinal Muscular Atrophy in New York State: Clinical Outcomes From the First 3 Years.
    Lee BH; Deng S; Chiriboga CA; Kay DM; Irumudomon O; Laureta E; Delfiner L; Treidler SO; Anziska Y; Sakonju A; Kois C; Farooq O; Engelstad K; Laurenzano A; Hogan K; Caggana M; Saavedra-Matiz CA; Stevens CF; Ciafaloni E
    Neurology; 2022 Oct; 99(14):e1527-e1537. PubMed ID: 35835557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural history of infantile-onset spinal muscular atrophy.
    Kolb SJ; Coffey CS; Yankey JW; Krosschell K; Arnold WD; Rutkove SB; Swoboda KJ; Reyna SP; Sakonju A; Darras BT; Shell R; Kuntz N; Castro D; Parsons J; Connolly AM; Chiriboga CA; McDonald C; Burnette WB; Werner K; Thangarajh M; Shieh PB; Finanger E; Cudkowicz ME; McGovern MM; McNeil DE; Finkel R; Iannaccone ST; Kaye E; Kingsley A; Renusch SR; McGovern VL; Wang X; Zaworski PG; Prior TW; Burghes AHM; Bartlett A; Kissel JT;
    Ann Neurol; 2017 Dec; 82(6):883-891. PubMed ID: 29149772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nusinersen treatment of spinal muscular atrophy - a systematic review.
    Albrechtsen SS; Born AP; Boesen MS
    Dan Med J; 2020 Aug; 67(9):. PubMed ID: 32800069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function.
    Swoboda KJ; Prior TW; Scott CB; McNaught TP; Wride MC; Reyna SP; Bromberg MB
    Ann Neurol; 2005 May; 57(5):704-12. PubMed ID: 15852397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study.
    Crawford TO; Swoboda KJ; De Vivo DC; Bertini E; Hwu WL; Finkel RS; Kirschner J; Kuntz NL; Nazario AN; Parsons JA; Pechmann A; Ryan MM; Butterfield RJ; Topaloglu H; Ben-Omran T; Sansone VA; Jong YJ; Shu F; Zhu C; Raynaud S; Lago TR; Paradis AD; Foster R; Chin R; Berger Z;
    Muscle Nerve; 2023 Aug; 68(2):157-170. PubMed ID: 37409780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newborn Screening for Spinal Muscular Atrophy: A 2.5-Year Experience in Hyogo Prefecture, Japan.
    Sonehara S; Bo R; Nambu Y; Iketani K; Lee T; Shimomura H; Ueda M; Takeshima Y; Iijima K; Nozu K; Nishio H; Awano H
    Genes (Basel); 2023 Dec; 14(12):. PubMed ID: 38137033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Electrophysiological Changes in Pediatric Spinal Muscular Atrophy after 2 Years of Nusinersen Treatment.
    Axente M; Mirea A; Sporea C; Pădure L; Drăgoi CM; Nicolae AC; Ion DA
    Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.